Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be
most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia …

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder affecting
hematopoietic stem cells and affects predominantly granulocyte progenitor line. It is …

Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against
the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase has …

High-dose imatinib improves cytogenetic and molecular remissions in patients with
pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia …

Aim: to analyze the clinical characteristics of patients with chronic phase CML and evaluate
complete hematologic responses (CHR) and overall survival (OS) after treatment with …

BACKGROUND AND OBJECTIVES: Imatinib mesylate induces a complete cytogenetic
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …

Imatinib is a relatively specific inhibitor of the BCR/ABL tyrosine kinase, effective in chronic
myeloid leukemia (CML). The aim of our study was to analyse the frequency and type of …

Fifty patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia
(CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median …

Background: Chronic myeloid leukemia (CML) is a clonal myeloid proliferative disorder of
primitive haemopoietic progenitor cells. The incidence of CML ranges between 10 and 15 …

To validate patient responses to imatinib mesylate, which induces hematologic and
cytogenetic remission and, consequently, modifies the progression of chronic myeloid …